Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002
Gabriele Calaminus(University Hospital Bonn), G. Schellong(Uniwersytecki Szpital Dziecięcy), Susanne Singer(Rostock University of Music and Theatre), C. Teske(University Hospital Münster), Jürgen Brämswig(University Hospital Münster), Hans‐Henning Flechtner(Jagiellonian University), Katja Baust(University Hospital Bonn), W Dörffel(Helios Hospital Berlin-Buch), Marianne Riepenhausen(University Hospital Münster), Andreas Hinz(Leipzig University)
Cited by 51
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
|JNCI Journal of the National Cancer Institute|1993|15.9k
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample
|Journal of Affective Disorders|2016|452
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419